Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Dermatology

How to Treat Severe Itching in Sjögren-Larsson Syndrome

At a Glance

Severe itching in Sjögren-Larsson syndrome is driven by a buildup of leukotriene B4. Standard antihistamines rarely work. Effective management requires aggressive daily skincare to repair the skin barrier and systemic medications like zileuton or dupilumab to target internal inflammation.

Severe itching, medically known as pruritus, is one of the most distressing symptoms of Sjögren-Larsson syndrome (SLS), often leading to intense scratching, sleep disruption, and decreased quality of life. The itching in SLS is driven by the body’s inability to break down certain fats, leading to a buildup of fatty aldehydes and an inflammatory molecule called leukotriene B4 (LTB4) [1][2].

Because the itch is rooted in this unique metabolic process, standard over-the-counter itch creams and common oral antihistamines (which target histamine, not LTB4) are rarely enough on their own. Treating severe pruritus in SLS requires a two-tiered approach: aggressive daily skincare to manage the dry, thickened skin (ichthyosis), and advanced systemic medications that target the internal inflammation.

The Foundation: Standard Skincare Approaches

In individuals with SLS, the skin’s barrier is compromised due to a lack of specific fats (acylceramides) [3][4]. Rebuilding and softening this barrier is the first step in managing itch, though finding the time and energy for extensive skincare regimens can be exhausting, especially when balancing the physical challenges of SLS like spasticity.

  • Keratolytics: These are special creams or lotions containing ingredients like urea or lactic acid that work by loosening and shedding the thick, scaling skin typical of SLS [5]. Doctors may recommend higher concentrations of these ingredients for severe thickening.
    • Important Safety Warning: Salicylic acid is generally avoided in young children with ichthyosis due to the risk of toxic absorption over large body surface areas. Additionally, alpha-hydroxy acids (like lactic acid) and urea will cause severe stinging and burning if applied to raw, open, or actively scratched skin. Use bland ointments on broken skin until it heals.
  • Intensive Moisturizers (Emollients): Frequent application of specialized moisturizers helps lock water into the skin and repair the damaged barrier [6]. The “soak and smear” technique—applying thick emollients to damp skin within three minutes of exiting the bath—is highly effective. Keeping the skin intensely hydrated reduces the physical triggers for scratching.

Advanced Therapies: When Creams Aren’t Enough

When topical treatments cannot control the intractable itching, dermatologists and geneticists may look to systemic medications (treatments that work throughout the entire body) to turn off the internal itch signals.

Targeting the Source: Zileuton

Because the severe itch in SLS is closely linked to high levels of the inflammatory molecule LTB4, blocking its production can be highly effective [3]. Zileuton is an oral medication known as a 5-lipoxygenase inhibitor, which stops the body from producing LTB4 [2].

  • In clinical studies of patients with SLS, treatment with zileuton resulted in significantly decreased LTB4 levels and major improvements in severe itching and general well-being [2].
  • This treatment targets the specific metabolic driver of itch in SLS, requiring careful medical supervision and regular liver monitoring.

Biologic Therapies: Dupilumab

If itching remains severe, doctors may consider biologic medications like dupilumab. Dupilumab is a targeted injection that blocks specific immune signals (IL-4 and IL-13) responsible for allergic inflammation and severe itch [7][8].

  • While large clinical trials specific to SLS are lacking, dupilumab is increasingly being used off-label by pediatric dermatologists to successfully treat intractable itch in other rare, severe ichthyosis conditions, such as Netherton syndrome [9][10].
  • It works by suppressing the overactive immune pathways that cause chronic scratching, offering a potential lifeline for families losing sleep to pruritus.

Comparing Advanced Therapies

Therapy How it is taken Main target Key Considerations
Zileuton Oral pill Blocks LTB4 production Directly addresses the SLS metabolic defect; requires regular liver function blood tests.
Dupilumab Injection Blocks IL-4/IL-13 Used off-label for severe itch in related skin conditions; requires insurance navigation.

Emerging Treatments on the Horizon

Researchers are currently investigating new therapies that address the root cause of SLS. Aldehyde-scavenging drugs, such as reproxalap, are being studied for their ability to safely trap and remove toxic fatty aldehydes before they can cause skin damage and inflammation [11][12]. While these are still in the investigational stages, they represent hope for more direct treatments in the future.

Common questions in this guide

What causes the severe itching in Sjögren-Larsson syndrome?
The intense itch is caused by a metabolic inability to break down certain fats, leading to a buildup of an inflammatory molecule called leukotriene B4 (LTB4). Because the root cause is metabolic, standard allergy medicines and over-the-counter creams often do not work.
Are over-the-counter itch creams enough to treat SLS pruritus?
Usually, no. Standard itch creams and antihistamines do not target the specific internal inflammation causing the itch. Effective treatment typically requires a combination of intensive prescription skincare and systemic medications.
What is zileuton and how does it help SLS?
Zileuton is an oral medication that stops the body from producing LTB4, the molecule largely responsible for severe itching in SLS. It directly targets the internal source of the itch, though it requires regular liver monitoring by a doctor.
Can dupilumab be used for Sjögren-Larsson syndrome?
While not officially approved specifically for SLS, pediatric dermatologists sometimes use dupilumab off-label for intractable itch. This biologic injection blocks the immune signals responsible for chronic scratching.
What skincare ingredients should be avoided on SLS skin?
Salicylic acid should generally be avoided in young children due to the risk of toxic absorption over large areas. Additionally, keratolytics like urea or lactic acid should never be applied to raw or actively scratched skin, as they will cause severe stinging and burning.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Could the severe itching be driven primarily by LTB4 accumulation, and is it appropriate to test those levels?
  2. 2.Given the severity of the itching, am I (or is my child) a candidate for a trial of a 5-lipoxygenase inhibitor like zileuton?
  3. 3.If standard topical therapies are failing, how do we navigate insurance approval for off-label biologics like dupilumab?
  4. 4.What are the safest keratolytic concentrations to use on this specific skin thickness, keeping in mind the risks of skin absorption?
  5. 5.Can we coordinate our dermatology plan with a geneticist to ensure our skincare routine aligns with our metabolic management?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    A rare case of Sjogren-Larsson syndrome with recurrent pneumonia and asthma.

    Tavasoli A, Sayyahfar S, Behnam B

    Korean journal of pediatrics 2016; (59(6)):276-9 doi:10.3345/kjp.2016.59.6.276.

    PMID: 27462357
  2. 2

    Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome.

    Willemsen MA, Lutt MA, Steijlen PM, et al.

    European journal of pediatrics 2001; (160(12)):711-7 doi:10.1007/s004310100838.

    PMID: 11795678
  3. 3

    Beyond retina in Sjogren-Larsson syndrome.

    Pawar N, Meenakshi R, Maheshwari D, et al.

    Indian journal of ophthalmology 2022; (70(7)):2727-2728 doi:10.4103/ijo.IJO_2994_21.

    PMID: 35791223
  4. 4

    Ceramide profiling of stratum corneum in Sjögren-Larsson syndrome.

    Arai A, Takeichi T, Wakamoto H, et al.

    Journal of dermatological science 2022; (107(3)):114-122 doi:10.1016/j.jdermsci.2022.08.003.

    PMID: 35973883
  5. 5

    Clinical and molecular characterization and response to acitretin in three families with Sjögren-Larsson syndrome.

    Vural S, Vural A, Akçimen F, et al.

    International journal of dermatology 2018; (57(7)):843-848 doi:10.1111/ijd.14013.

    PMID: 29704247
  6. 6

    Genotype and phenotype variability in Sjögren-Larsson syndrome.

    Weustenfeld M, Eidelpes R, Schmuth M, et al.

    Human mutation 2019; (40(2)):177-186 doi:10.1002/humu.23679.

    PMID: 30372562
  7. 7

    Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.

    D'Erme AM, Romanelli M, Chiricozzi A

    Drug design, development and therapy 2017; (11()):1473-1480 doi:10.2147/DDDT.S113192.

    PMID: 28553077
  8. 8

    Dupilumab: A New Paradigm for the Treatment of Allergic Diseases.

    Sastre J, Dávila I

    Journal of investigational allergology & clinical immunology 2018; (28(3)):139-150 doi:10.18176/jiaci.0254.

    PMID: 29939132
  9. 9

    Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.

    Yan S, Wu X, Jiang J, et al.

    Frontiers in immunology 2022; (13()):1054422 doi:10.3389/fimmu.2022.1054422.

    PMID: 36569942
  10. 10

    Dupilumab in Inflammatory Skin Diseases: A Systematic Review.

    Olbrich H, Sadik CD, Ludwig RJ, et al.

    Biomolecules 2023; (13(4)) doi:10.3390/biom13040634.

    PMID: 37189381
  11. 11

    Sjögren-Larsson syndrome: A biochemical rationale for using aldehyde-reactive therapeutic agents.

    Rizzo WB, S'aulis D, Dorwart E, Bailey Z

    Molecular genetics and metabolism reports 2022; (30()):100839 doi:10.1016/j.ymgmr.2021.100839.

    PMID: 35242571
  12. 12

    Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.

    Rizzo WB

    Expert opinion on orphan drugs 2016; (4(4)):395-406 doi:10.1517/21678707.2016.1154453.

    PMID: 27547594

This page provides educational information about managing itching in Sjögren-Larsson syndrome. Always consult your dermatologist or geneticist before starting new topical or systemic therapies.

Get notified when new evidence is published on Sjögren-Larsson syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.